These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22121371)

  • 1. Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.
    Arefiev K; Fiorentino DF; Chung L
    Int J Rheumatol; 2011; 2011():201787. PubMed ID: 22121371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review.
    Rademacher JG; Wincup C; Tampe B; Korsten P
    J Scleroderma Relat Disord; 2020 Jun; 5(2):159-164. PubMed ID: 35382024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
    Silva C; Solanki KK; White DHN
    Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.
    Fernández-Codina A; Cañas-Ruano E; Pope JE
    J Scleroderma Relat Disord; 2019 Jun; 4(2):102-110. PubMed ID: 35382396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iloprost infusion through elastomeric pump in the treatment of Raynaud's phenomenon and digital ulcers.
    Fartura Braga Temido MH; Gomes M; Parente F; Santos L
    J Scleroderma Relat Disord; 2019 Feb; 4(1):NP1-NP4. PubMed ID: 35382145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
    Jokar MH; Baghbani B; Geraylow KR; Shariati J; Mehrad-Majd H; Mirfeizi Z; Hashemzadeh K
    Reumatologia; 2022; 60(6):392-398. PubMed ID: 36683833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
    Linnemann B; Erbe M
    Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].
    Ben Salem T; Tougorti M; Bziouech S; Lamloum M; Khanfir M; Ben Ghorbel I; Houman MH
    J Med Vasc; 2018 Feb; 43(1):29-35. PubMed ID: 29425538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.
    Chatterjee S
    Curr Treat Options Cardiovasc Med; 2010 Apr; 12(2):185-204. PubMed ID: 20842555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnosis and treatment of Raynaud's phenomenon: a practical approach.
    Pope JE
    Drugs; 2007; 67(4):517-25. PubMed ID: 17352512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis.
    Knock GA; Terenghi G; Bunker CB; Bull HA; Dowd PM; Polak JM
    J Invest Dermatol; 1993 Jul; 101(1):73-8. PubMed ID: 8331298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raynaud's Phenomenon with Focus on Systemic Sclerosis.
    Maciejewska M; Sikora M; Maciejewski C; Alda-Malicka R; Czuwara J; Rudnicka L
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
    Parisi S; Bruzzone M; Centanaro Di Vittorio C; Laganà A; Peroni CL; Fusaro E
    Reumatismo; 2014 Mar; 65(6):286-91. PubMed ID: 24705032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.